Michael J. Baine, M.D., Ph.D.

Assistant Professorbaine.jpg

Education:

  1. B.S. Biochemistry. Loyola Marymount University, Los Angeles, CA (2003-2007)
  2. Ph.D. Cancer Biology. University of Nebraska Medical Center (2009-2012)
  3. M.D. University of Nebraska Medical Center (2007-2014)
  4. Intern Year in Internal Medicine. University of Nebraska Medical Center (2014-2015)
  5. Residency in Radiation Oncology. University of Nebraska Medical Center (2019)

Board Certification: 

Professional Memberships:

American Brachytherapy Society (ABS), Member 2015 – Present
American Society for Radiation Oncology (ASTRO), Member 2015 – Present
Association of Residents in Radiation Oncology (ARRO), Member 2015 – Present
Radiological Society of North America (RSNA), Member 2015 – Present

Clinical & Research Interests:

Research: My research is focused on the development and testing of novel and cutting edge diagnostic and therapeutic strategies for GI and GU malignances with specific focus on pancreas adenocarcinoma, prostate cancer, and urothelial carcinoma of the bladder.  

Research Projects:

Pancreatic cancer is among most lethal and aggressive malignancies. With improving median overall survival for early stage resected cases, early detection is key to improved survival. A plethora of biomarkers have been tested out to date, however, pancreatic tumor heterogeneity has compounded the issue and no single marker is of high accuracy to differentiate individual subtypes of PC from control. Henceforth after decades of ongoing efforts to discover and validate biomarkers for PC, CA 19.9, with poor sensitivity and specificity, remains the best molecule available for prognosis. In our preliminary studies, based on the innovative computational pipeline based on transcriptome data from tumor subtypes, we have identified and developed a 16- biomarker combination based on the individual subtypes of PC that provides high accuracy for differentiating precursor, early and late stages of PC from high-risk control groups (chronic pancreatitis (CP), low-grade IPMN). Further, we have developed an immunoassay and evaluated combinatorial biomarker performance in a comprehensive training set. In large-scale serum studies, we observed that MUC4, TFF1, MUCSAC and CA19.9 in combination significantly improves accuracy over CA19.9 in differentiating early PC from controls. Based on this background and our preliminary studies, we hypothesize that a systematically developed, additive, combinatorial panel in coniunction with ultrasensitive state-of-art biomarker detection and imaging technology, will provide a crucial and clinically useful biomarker set and technology for the enriching of the high-risk malignant population of PC. Further, in conjunction with machine learned imaging tools, it will provide a much needed test for on-time detection of pancreatic tumors. 

For the majority of patients diagnosed with clinically localized prostate cancer, radical prostatectomy (RP) remains a treatment option with a high rate of cure. However, in a proportion of these patients, final pathology reveals high-risk features including extracapsular extension, seminal vesicle invasion, and positive surgical margins. This population, which represents approximately 30% of all patients who undergo RP, presents a clinical conundrum. The presence of these features increases the likelihood of both biochemical and clinical failure following RP and thus presses the consideration of adjuvant radiation treatment. Adjuvant therapy allows for the treatment of the least amount of residual cancer cells possible as it reduces the time allowed for the residual cancer cells to grow following RP. Alternatively, awaiting biochemical failure and offering early salvage therapy brings with it the advantage of preventing overtreatment of the approximately 35% who will never suffer biochemical failure following RP despite the presence of high-risk features. 

To date, it remains unclear as to which if these two treatment strategies are superior. Multiple past clinical trials have been reported which suggest an advantage to adjuvant treatment but suffered from significant design flaws which undermine their applicability to every day clinical practice. The ARO 96-02 trial randomized patients with pT3 pN0 prostate cancer or those who underwent a R1 resection to either adjuvant radiation therapy (RT) or no further therapy. Adjuvant RT was associated with a near doubling of progression-free survival at 10 years (35% vs 56%). However, it is unclear as to what the 10-year PFS would be if patients in the wait-and-see arm were allowed to undergo salvage RT following biochemical failure. EORTC 22911 randomized a similar patient population to adjuvant therapy versus watchful waiting but, in this case, allowed salvage treatment in the event of biochemical failure for patients assigned to the watchful waiting group. Again, adjuvant RT appeared to improve progression-free survival. However, it is noteworthy that this trial did not require undetectable PSAs following RP and thus both treatment arms were contaminated by patients with biochemical evidence of active disease at the time of randomization. Lastly, SWOG 8794 also randomized patients with pT3 disease or positive margins to adjuvant RT versus observation with salvage RT allowed following biochemical failure in the observation arm. Similarly to the other two studies, progression-free survival was improved with adjuvant RT with a strong trend toward improved metastasis-free survival as well (p=0.06) but, like the EORTC trial, did not require undetectable PSA prior to randomization. Further, only approximately 35% of the patients who suffered biochemical failure on the observation arm underwent salvage RT. To further investigate the adjuvant versus early salvage debate, Hwang and colleagues undertook a multi-institutional retrospective review of 1566 patients who underwent RP and were found to have pT3 disease or positive margins. When compared to early salvage RT (PSA < 0.5 ng/mL), adjuvant RT was associated with improved biochemical PFS, distant metastasis-free survival, and overall survival. However, though clearly representing a higher risk population with increased risk for the presence of subclinical distant metastatic disease, patients with persistently positive PSA following RP were analyzed within the salvage RT group; a fact which may significantly affect the interpretation of the study’s results.

 In light of this remaining lack of clarity in the adjuvant versus salvage RT debate, we are investigating which patients with high-risk features are at highest risk for post-RP failure and thus may benefit the most from adjuvant treatment using cutting-edge imaging and molecular biological techniques.   

Urothelial carcinoma of the bladder currently ranks as the 4th leading cancer diagnosis and 8th leading cause of cancer-related death in males, comprising 62,380 and 12,520 patients, respectively.  Treatment of this malignancy varies widely depending on tumor stage and the surgical candidacy of the patient. Treatment in the metastatic setting remains difficult, with only 5% of patients surviving 5 years post-diagnosis utilizing current treatment regimens.  First line therapy in the metastatic setting consists of platinum-based chemotherapy regimens which yield median overall survivals of 9-15 months. Adjunct treatments such as surgical interventions or radiation therapy are reserved for palliative purposes in this setting, used primarily for pelvic pain or hematuria.   

Until recently, no consensus second-line therapy existed for patients who progressed through, or were ineligible for, platinum-based chemotherapy. However, with the recently reported results of the KEYNOTE-045 trial demonstrating that Pembrolizumab provides a 3 month survival advantage over various chemotherapy regimens in the platinum-refractory setting as well as a phase-II study revealing a 15.9 month overall survival with Atezolizumab in platinum-ineligible patients, the use of PD-L1 inhibitors have emerged as accepted treatment options.   

The utility of PD-L1 inhibitors in urothelial carcinoma was previously suggested through multiple past studies. Bladder cancer is established to have high somatic mutational burden, widely considered to be a marker of likely immunotherapeutic efficacy due to formation of neoantigens. Further, PD-L1 expression has been found to be present in bladder cancer samples from patients with rate of PD-L1 expression correlating with patient tumor stage; in one study, 27% of T1 tumors expressed PD-L1 while this expression increased to 72% in muscle-invasive disease.  Importantly, PD-L1 expression was also found to be a significant predictor of both locoregional and distant failure following primary chemoradiotherapy as well as patient overall survival, suggesting that PD-L1-mediated immune evasion plays an important role in bladder cancer outcomes.   

The ability for radiation therapy, when used in combination with immunomodulators, to further improve therapeutic efficacy is becoming increasingly accepted. Though radiation is classically considered to be solely a local therapy, multiple studies have shown evidence of out-of-field tumor response following focal radiation treatments. This systemic response to localized radiation therapy, termed the abscopal effect, is thought to likely be immune-mediated. This consideration is strongly supported by the increasing pre-clinical evidence demonstrating improved local and distant anti-tumor activity when radiation and immune checkpoint inhibitors are combined as compared to either treatment provided individually. With this evidence, the combination of immune checkpoint inhibition and radiotherapy is currently being investigated in the clinic though multiple completed or ongoing clinical trials, the majority of which were recently summarized by Gong et al. This combination is also currently under investigation through an ongoing clinical trial using the combination of conventionally fractionated radiation therapy with durvalumab, a PD-1 inhibitor, in patients with non-metastatic urothelial carcinoma of the bladder.   

To date, no studies exist which investigate the efficacy of combining radiation therapy with immunomodulation in the setting of metastatic urothelial carcinoma of the bladder.  As such, we are testing the combination of short course radiation therapy with PD-L1 inhibition in a reliable transgenic, immunocompetent mouse model with the goal of rapidly translating this to a phase I/II clinical trial.

Research Projects:
Head & Neck Anxiety Reduction: A prospective randomized controlled study
Grant funded prospective study to assess the effects of virtual reality-based education to reduce anxiety in patients undergoing radiation to the head and neck region.

Pediatric Cross-sectional Analysis of Treatment Tolerance and Quality of Life
Cross-sectional observation study of side effects and perceived quality of life after radiotherapy.

Publications:

Full Length Manuscripts:

  1. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011 January;1815(1):44-64. (Peer reviewed)
  2. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, Batra SK. Transcriptional Profiling of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients Identifies Novel Genes with Potential Diagnostic Utility. PLoS ONE 2011 January; 6(2):e17014. (Peer reviewed).
  3. Baine MJ, Sahaq F, Lin C, Chakraborty S, Batra SK. Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS ONE 2011 July; 6(6):e21052. (Peer Reviewed).
  4. Baine MJ, Ochi N, Wallace MB, Woodward TA, Thomas CS, Guha S, Raimondo M. Ngal in Pancreatic Juice Help to Discriminate Chronic Pancreatitis and Pancreatic Cancer from Healthy Controls. Gastroenterology 2011; 140(5). (Peer reviewed).
  5. Baine MJ, Menning M, Smith LM, Mallya K, Kaur S, Rachagani S, Chakraborty S, Sasson AR, Brand RE, Batra SK. Differential Gene Expression Analysis of Peripheral Blood Mononuclear Cells Reveals Novel Test for Early Detection of Pancreatic Cancer. Cancer Biomarkers 2011/2012, 1-14. (Peer reviewed).
  6. Rachagani S, Torres MP, Kumar S, Haridas D, Baine MJ, Macha MA, Kaur S, Ponnusamy M, Dey P, Sashacharyulu P, Johansson S, Jain M, Wagner KU, Batra SK. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Journal of Hematology & Oncology 2012 5:68. (Peer reviewed).  
  7. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early Diagnosis of Pancreatic Cancer: Challenges and new developments. Biomarkers Medicine 2012 6(5), 597-612. (Peer reviewed).
  8. Baine MJ, Kaur S, Guha S, Ochi N, Chakraborty S, Mallya K, Thomas C, Crook J, Wallace M, Woodward T, Jain M, Singh S, Sasson A, Skinner V, Raimondo R, Batra SK. Neutrophil Gelatinase-Associated Lipocalin, Macrophage Inhibitory Cytokine 1, and Carbohydrate Antigen 19-9 in Pancreatic Juice: Pathobiologic Implications in Diagnosing Benign and Malignant Disease of the Pancreas. Pancreas 2013 Apr;42(3):494-501. (Peer reviewed).  
  9. Baine MJ, Chakraborty S, Kaur S, Mallya K, Smith LM, Sasson AR, Brand RE, Guha S, Jain M, Wittel U, Singh SK, Batra SK. Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer. PLoS ONE 2013;8(2):e55171. (Peer reviewed).
  10. Baine MJ and Lin C. Radiation Therapy Improves Survival Outcome in Pancreatic Adenocarcinoma: Comparison of a 15-year institutional experience at the University of Nebraska Medical Center with SEER data. Journal of Radiotherapy. 2014 Jan 27;2014.708317. (Peer reviewed).
  11. Baine MJ, Soucheck JJ, Lester K, Lin C, Chen S, Kaur S, Sahak F, Batra SK. Unbiased Analysis of Pancreatic Cancer Radiation Resistance Reveals Cholesterol Biosynthesis as a Potent Novel Target for Radiosensitization. Br J Cancer. 2014 Sep 9;111(6):1139-49. (Peer reviewed). 
  12. BaineKumar S, Torres MP, Kaur S, Rachagani S, Joshi S, Johansson SL, Momi N, Baine MJ, Gilling CE, Smith LM, Wyatt TA, Jain M, Joshi SS, Batra SK. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Oncogene. 2015 Apr 16;34(16):2052-60. (Peer reviewed).
  13. Baine13. Kaur S, Sharma N, Krishn SR, Lakshmanan I, Rachagani S, Baine MJ, Smith LM, Lele SM, Sasson AR, Guha S, Mallya K, Anderson JM, Hollingsworth MA, Batra SK. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.  Clin Cancer Res.  2014 Feb 1;20(3):688-700. (Peer reviewed).
  14. Baine MJ, Shonka N, Zhang C. Combining Radiation Therapy with Targeted Therapies in Intracranial Metastatic Disease. JSIN. 2016 Nov 22. (Peer reviewed).
  15. Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta. 2017 Aug; 1868(1):69-92. (Peer reviewed).
  16. Bennion N, Baine MJ, Malouff T, Zhen W. Osteosarcoma of the Larynx: Treatment Outcomes and Patterns of Failure Analysis. Rare Tumors. 2017 Mar 24;9(1)6955. (Peer reviewed).  
  17. Baine MJ, Lin C. Genome-based modeling for adjusting radiotherapy dose (GARD)-a significant step toward the future of personalized radiation therapy. Transl Cancer Res. 2017 Mar;6(2)S418-420. (Peer reviewed).  
  18. Baine MJ, Dorious T, Bennion N, Alam M, Smith L, Zhen W, Ganti A. Chemoradiotherapy for locally advanced squamous cell carcinoma of the oropharynx: Does completion of systemic therapy affect outcomes? Oral Oncol. 2017 Oct;73:105-110. (Peer reviewed). 
  19. Baine MJ, Lin C. Radiation therapy in the treatment of resectable locally advanced gastric adenocarcinoma: present and future. Remed Open Access. 2017;2:1070. (Peer reviewed).  
  20. Baine MJ, Dorius T, Bennion N, Smith L, Zhen W, Ganti A. Weight loss and percutaneous endoscopic gastrostomy tube placement during chemoradiotherapy for locally advanced cancer of the oropharynx do not negatively impact outcomes. Front Oncol. 2017 Dec 05;7:299. (Peer reviewed).  
  21. Baine MJ, Verma V, Schonewolf CA, Lin C, Simone CB II. Histology significantly affects recurrence and survival following SBRT for early-stage non-small cell lung cancer. Lung Cancer. 2018 e pub (Peer reviewed) 
  22. Sleightholm RL, Baine MJ. Commentary: Chemoradiotherapy for locally advanced squamous cell carcinoma of the oropharynx: Does completion of systemic therapy affect outcomes. Journal of Cancer Treatment and Diagnosis. 2018; 2(2): 8-10. (Peer Reviewed)  
  23. Baine MJ, Sleightholm RL, Lin C. Incidence and patterns of locoregional failure following stereotactic body radiation therapy (SBRT) for pancreatic adenocarcinoma. PRO. 2018 e pub. (Peer Reviewed)  
  24. Bennion N, Baine MJ, Wahl AO. Accelerated Partial Breast Radiotherapy: A Review of the Literature and Future Directions. Gland Surgery. 2018 e pub. (Peer Reviewed) 
  25. Baine MJ, Sleightholm RL, Nielsen B, Smith LM, Verma V, Lin C. Outcomes of Stereotactic Body Radiation Therapy versus Non-Radiotherapeutic Ablative Procedures for Early Stage Non-Small Cell Lung Cancer: A Comparative Analysis Using the National Cancer Database. JNCCN. 2018 e pub. (Peer Reviewed)  
  26. Hill TK, Baine MJ, Verma V, Alam M, Lyden ER, Lin C, Connolly EP, Zhang C. Patterns of Care in pediatric Craniopharyngioma: Outcomes Following Definitive Radiotherapy. Anticancer Research. 2019 e pub. (Peer Reviewed)  
  27. Kaur S, Baine MJ, Guha S, Smith L, Brand R, Batra SK. A Multi-institutional Study of MUC5AC in Pancreatic Juice: Hope for early diagnosis. (Submitted)  
  28. Baine MJ, McAllister J, Yu L, Du Q, Jiang H, Zhang C, Yu H, Zhang D. Stability analysis of radiomic features across 4D respiratory breathing phases for lung tumors. (Submitted)  
  29. Bennion NR, Baine MJ, Jacobs K, Denniston K, Poole M, Wilson K, Driewer J, Blessie G, Headley M, Poole C, McMahon R, Zhou S, Zhang M, Lin C, Wahl A, Yager A, Enke C, Zhen W. Six sigma optimizations for workflow and quality improvement in the radiation oncology clinic. (Submitted)  
  30. Baine MJ, Wu G, Zhao N, Li S, Lin C. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. (Submitted)  
  31. Baine MJ, McLaughlin M, Ryckman J, Verma V, Alam M, Smith LM, Lin C. Radiation-induced lymphopenia following SBRT to the lung: dosimetric parameters and its impact on local, regional, and distant control. (Submitted)
  32. Baine MJ, Lester K, Kumar S, Batra SK. Establishment of a Mathematical Model for MUC4 Regulation by Retinoic Acid. (In preparation)  
  33. Baine MJ, Sleightholm RL, Lin C, Jain M, Batra SK. Effect of Concurrent Statin Therapy on Relative Radiosentivity of Pancreatic Adenocarcinoma. (In Preparation)  
  34. Baine MJ, Sleightholm RL, Bennion N, Lin C. SBRT to the liver: a single institutional experience. (In preparation)
  35. Seshacharyulu P, Baine MJ, Rachagani S, Souchek JJ, Jain M, Lin C, Batra SK. Zoledroinic acid acts as a potent, clinically applicable, radiosensitizer for pancreatic adenocarcinoma treated with stereotactic body radiation therapy. (In preparation)
  36. Sleightholm RL, Neilsen B, Enke C, Baine MJ. The effect of Omega-3 fish oil in outcomes following definitive radiation therapy for intermediate and high-risk prostatic adenocarcinoma. (In preparation)
  37. Sleightholm RL, Neilsen B, Enke C, Baine MJ. Agent orange exposure affects natural history of prostate cancer treated with definitive radiation therapy. (In preparation)
  38. Baine MJ, Sleightholm RL, McAllister J, Lin C, Ryckman J, Zheng D. Prognostication of locoregional and distant control following SBRT for adenocarcinoma of the pancreas: an advanced radiomics analysis. (In preparation)
  39. Sleightholm RL, Neilsen B, Wahl AO, Bennion N, Baine MJ. The effect of percent positivity of hormone receptors on treatment outcomes in breast cancer. (In preparation) 
  40. Sleightholm RL, Neilsen B, Wahl AO, Bennion N, Baine MJ. Interaction of tumor histology with radiation fractionation schedules. (In preparation)
  41. Baine MJ, Zima L, Zhang C, Zhang D. Novel prognostication of glioblastoma using advanced radiomics features. (In Preparation)
  42. Baine MJ, Friedman F, Sleightholm RL, Zhang C. Interaction of antihypertensives and stereotactic radiotherapy in early-stage non-small cell lung cancer. (In Preparation) 
  43. Baine MJ, Lin C, Zhang D. Radiomic features are superior to clinical parameters in predicting outcome sin pancreatic adenocarcinoma. (In Preparation)
  44. Baine MJ, Friedman F, Sleightholm RL, Zhang C. Dosimetric analysis of efficacy and toxicity of linear accelerator-based stereotactic radiosurgery for trigeminal neuralgia. (In Preparation)
  45. Baine MJ, Zima L, Sleightholm RL, Punsoni M, Zhang C. Currently accepted pathologic features poorly predict risk of recurrence in grade 2 meningiomas. (In Preparation) 
  46. Baine MJ, Parr E, Sleightholm RL, Zhang C. Radiation alone versus sequential chemoradiotherapy in glioblastoma patients with poor performance status. (In preparation) 
  47. Sleightholm RL, Baine MJ, Lin C, Oupicky D. Chloroquine nanoparticles significantly radiosensitize pancreatic adenocarcinoma treated with SBRT. (In Preparation) 

Book Chapters:

  1. Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Set-up Error Correction Using Internal Markers and its Association with the Patient’s Body Mass Index. Chi Lin, Shifeng Chen, Michael J. Baine. Modern Practices in Radiation Therapy, 2012.  
  2. Pancreatic Cancer Biomarkers. Michael J. Baine, Sukhwinder Kaur, Aaron R. Sasson, Surinder K. Batra. Encyclopedia of Cancer, Springer 2012. 
  3. Quantitative Real-Time PCR Expression Analysis of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients. Michael J. Baine, Surinder K. Batra. Methods in Molecular Medicine: Pancreatic Cancer, Springer 2013.
  4. Immunohistochemistry of Pancreatic Neoplasia. Sukhwinder Kaur, Michael J. Baine, Surinder K. Batra. Methods in Molecular Medicine: Pancreatic Cancer, Springer 2013.  
  5. Pancreatic Cancer Biomarkers. Michael J. Baine, Sukhwinder Kaur, Aaron R. Sasson, Surinder K. Batra. Encyclopedia of Cancer, Springer 2015.

Abstracts:

  1. NGAL from Pancreatitis to Pancreatic Cancer: Diagnostic and Prognostic Implications in Patients. Chakraborty S., Sukhwinder Kaur, Nicholas Moniaux, Venkata Muddana, Michael J. Baine, Uwe A. Wittel, Kavita Mallya, Georgios I Papachristou, David Whitcomb, Aaron R. Sasson, Randall E. Brand, Michael A. Hollingsworth and Batra S.K.  Poster Presented at the 2009 National Cancer Institute Translational Science Meeting (November 5-7).  
  2. Identification of Differentially Expressed Transcripts in Peripheral Blood Mononuclear Cells (PBMCS) of Patients with Pancreatic Cancer Yielding Several Genes with Potential Diagnostic and Prognostic Implications. Michael Baine, Subhankar Chakraborty, Lynette Smith, Kavita Mallya, Aaron Sasson, Surinder K. Batra. Poster Presented at the 2010 Midwest Student Biomedical Research Forum (February 20th).  
  3. Transcriptional Profiling in Peripheral Blood Mononuclear Cells of Patients with Pancreatic Cancer. Michael Baine. Presented Orally at the Monthly SPORE meeting (March 4th, 2010).  
  4. Transcriptional Profiling in Peripheral Blood Mononuclear Cells of Patients with Pancreatic Cancer Identifies Several Genes with Potential Diagnostic and Prognostic Implications. Michael Baine, Subhankar Chakraborty, Lynette Smith, Kavita Mallya, Aaron Sasson, Surinder K. Batra. Poster Presented at the 2010 AACR Conference (April 17-21).  
  5. Elevated plasma NGAL and MIC-1 are novel biomarkers for the diagnosis of Pancreatic Adenocarcinoma. Subhankar Chakraborty, Michael Baine, Sukhwinder Kaur, Kavita Mallya, Maneesh Jain, Aaron R. Sasson, Surinder K. Batra. Poster Presented at the 2010 AACR Conference (April 17-21).
  6. Marital status and survival in pancreatic cancer patients: a SEER based retrospective analysis. Freshta Sahaq, Michael Baine, Chi Lin, Subhankar Chakraborty, Surrinder K. Batra. Poster Presented at 2010 SURP Research Colloquium (August 5th).
  7. Novel Biomarkers for the (Early) Diagnosis of Pancreatic Ductal Adenocarcinoma. Michael Baine. Presented Orally at the CRGP Student Seminar (October 29th, 2010).  
  8. Transcriptional Profiling in Peripheral Blood Mononuclear Cells of Patients with Pancreatic Cancer Identifies Several Genes with Potential Diagnostic and Prognostic Implications. Michael Baine, Subhankar Chakraborty, Lynette Smith, Kavita Mallya, Aaron Sasson, Surinder K. Batra. Poster Presented at the 2010 SPORE Retreat (December 6-7).  
  9. Potent Anti-proliferative, Anti-invasive and Anti-migratory Effects of Ocimum Sanctum (Holy Basil) Extract on Pancreatic Cancer Cells. Subhankar Chakraborty, Maria Torres Gonzales, Shinozu Tomohiro, Sukhwinder Kaur, Joshua Souchek, Satyanarayana Rachagani, Imayavaramban Lakshmanan, Michael  J. Baine, Apar K. Ganti, Ralph J Hauke, Erik D. Moore, Partha Mukhopadhyay, Surinder K. Batra. Presented as an Oral Presentation at the 2011 Midwest Student Biomedical Research Forum (February 19th).  
  10. Investigating the Diagnostic Potential of Pancreatic Juice Surrogate Markers in the Diagnosis of Chronic Pancreatitis and Pancreatic Cancer. Michael Baine, Sukhwinder Kaur, Subhankar Chakraborty, Kavita Mallya, Sushovan Guha, Surrinder K. Batra. Poster Presented at the 2011 Digestive Disease Week (May 7-10).  
  11. Potential of Pancreatic Juice Surrogate Marker(s) in the Diagnosis of Chronic Pancreatitis and Pancreatic Cancer: A Retrospective Study. Michael J. Baine, Sukhwinder Kaur, Sushovan Guha, Nobuo Ochi, Subhankar Chakraborty, Kavita Mallya, Colleen Thomas, Julia Crook, Michael B. Wallace, Timothy A. Woodward, Maneesh Jain, Aaron R. Sasson, Verna Skinner, Massimo Raimondo, and Surinder K. Batra. Poster Presented at National Cancer Institute Translational Research Meeting 2011 (July 28-29).  
  12. Induced Radiation Resistance Results in Changes in Cancer Stem-Cell Associated Markers. Freshta Sahak, Katherine Lester, Michael J. Baine, Sukhwinder Kaur, Moorthy Ponusamy, A. Priyanka Vas, Chi Lin, Shefeng Chen, and Surinder K. Batra. Poster Presented at 2011 SURP Research Colloquium (August 5th).  
  13. PBMC Multiplex PCR Assay Reveals Promising Markers for Differentiating Early Pancreatic Cancer from Chronic Pancreatitis. Michael J. Baine, Melanie Menning, Kavita Mallya, Sukhwinder Kaur, Satyanarayana Rachagani, Subhankar Chakraborty, Aaron R. Sasson, Randall E. Brand, Surrinder K. Batra. Poster Presented at the 2011 EDRN workshop (Sept. 13-16).  
  14. Radioresistance in Pancreatic Cancer: The Role of Autophagy. Michael J. Baine, Katherine Lester, Sukhwinder Kaur, Chi Lin, Shifeng Chen, and Surinder K. Batra. Poster Presented at 2011 meeting of the American Pancreatic Association (Nov 2-5). 
  15. RUNX3 is a Tumor Suppressor in Human Pancreatic Cancer. Maneesh Jain, Michael J. Baine, Shantibhusan Senapati, and Surinder K. Batra. Poster Presented at 2011 meeting of the American Pancreatic Association (Nov 2-5).  
  16. Connecting the Cords: Mucin MUC4 and Acute Phase Protein NGAL. Sukhwinder Kaur, Subhankar Chakroborty, Michael Baine, Zhimin Tong, Imay Lakshmanan, Sushovan Guha, Surinder K. Batra. Poster Presented at 2011 meeting of the American Pancreatic Association (Nov 2-5).  
  17. Differential Expression Analysis of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients Reveals Novel Test for Early Detection. Melanie Menning, Michael J. Baine, Kavita Mallya, Sukhwinder Kaur, Satyanarayana Rachagani, Subhankar Chakraborty, Aaron R. Sasson, Randall E. Brand, and Surrinder K. Batra. Poster Presented at the 2012 Midwest Student Biomedical Research Forum (February 18th).  
  18. NGAL, MIC-1 and CA19-9 in Pancreatic Juice: Pathobiological Implications in Diagnosing Benign and Malignant Disease of the Pancreas. Michael J. Baine, Sukhwinder Kaur, Subhankar Chakraborty, Kavita Mallya, Maneesh Jain, Shailender Singh, Aaron R. Sasson, and Surinder K. Batra. Oral Presentation at the 2012 Midwest Student Biomedical Research Forum (February 18th).  
  19. Unbiased Analysis of Pancreatic Cancer Radiation Resistance Reveals Cholesterol Biosynthesis as a Potent Novel Target for Radiosensitization. Michael J. Baine, Katherine Lester, Chi Lin, Shifeng Chen, Josh Souchek, Sukhwinder Kaur, Freshta Sahak, Surinder K. Batra. Oral Presentation at the 2012 ASTRO International Radiation Oncology Conference (October 31, 2012).  
  20. Radiation Therapy Improves Outcome in Pancreatic Adenocarcinoma: Comparison of a 15-yearinstitutional experiences at the University of Nebraska Medical Center with SEER data. Michael Baine and Chi Lin. Poster Presented at the 2013 ASTRO International Radiation Oncology Conference (September 23, 2013).  
  21. Does completion of chemotherapy predict recurrence in locally advanced oropharyngeal cancer? Morshed Alam, Michael J Baine, Lynette Smith, Apar K Ganti, Timothy Dorius, Nathan Bennion, Weining Zhen. Poster Presented at the 2017 UNMC COPH Student Research Day (April 5th, 2017). 
  22. Effect of focal radiation treatment using stereotactic body radiation therapy (SBRT) on the risk of locoregional recurrence in pancreatic adenocarcinoma. Michael J Baine and Chi Lin. Poster Presented at the 2017 ASTRO International Radiation Oncology Conference (September 26, 2017).  
  23. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. Guangyin Wu, Nan Zhao, Sicong Li, Michael J Baine, Chi Lin. Poster Presented at the 2017 ASTRO International Radiation Oncology Conference (September 26, 2017). 
  24. Stereotactic Body Radiotherapy versus Non-Radiotherapeutic Ablative Procedures for Early Stage Non-Small Cell Lung Cancer. Michael J Baine, Richard L Sleightholm, Beth Neilsen, David Oupicky, Lynette M Smith, Vivek Verma, Chi Lin. Poster Presented at the 2018 ASTRO International Radiation Oncology Conference (October 23, 2018).

Oral Presentations:

  1. Transcriptional Profiling in Peripheral Blood Mononuclear Cells of Patients with Pancreatic Cancer. Michael Baine. Presented Orally at the Monthly SPORE meeting (March 4th, 2010).  
  2. Novel Biomarkers for the (Early) Diagnosis of Pancreatic Ductal Adenocarcinoma. Michael Baine Presented Orally at the CRGP Student Seminar (October 29th, 2010). 
  3. NGAL, MIC-1 and CA19-9 in Pancreatic Juice: Pathobiological Implications in Diagnosing Benign and Malignant Disease of the Pancreas. Michael J. Baine, Sukhwinder Kaur, Subhankar Chakraborty, Kavita Mallya, Maneesh Jain, Shailender Singh, Aaron R. Sasson, and Surinder K. Batra. Oral Presentation at the 2012 Midwest Student Biomedical Research Forum (February 18th, 2012).  
  4. Unbiased Analysis of Pancreatic Cancer Radiation Resistance Reveals Cholesterol Biosynthesis as a Potent Novel Target for Radiosensitization. Michael J. Baine, Katherine Lester, Chi Lin, Shifeng Chen, Josh Souchek, Sukhwinder Kaur, Freshta Sahak, Surinder K. Batra. Oral Presentation at the 2012 ASTRO International Radiation Oncology Conference (October 31st, 2012).
  5. "My Finger Hurts", an Interesting Case Presentation and Discussion of Glioblastoma. Michael J. Baine and Adrien Epstein. UNMC MD/PhD Grand Rounds. (March 20th, 2014).  
  6. Pancreatic Adenocarcinoma-the ninja cancer. Michael J. Baine. Oral Presentation at the Greater Omaha Radiation Oncology Conference. (November 7th, 2015).